AB250. SOH26AB_0432. Ductal carcinoma in situ eradicated in patient treated with venetoclax and obinutuzumab: a case report

DCIS is a non-invasive malignancy confined within the basement membrane and considered a precursor to invasive breast cancer. Venetoclax, a selective BCL2 inhibitor, has shown synergy with endocrine therapy in oestrogen receptor (ER)-positive breast cancer (phase 1b trial, 2019). Obinutuzumab is an anti-CD20 monoclonal antibody with no reported data in ductal carcinoma in situ (DCIS).